Evidence map›Paper›PMID 38723187›Full record

ArticleProtein science : a publication of the Protein Society2024

An ensemble machine learning model generates a focused screening library for the identification of CDK8 inhibitors.

Tony Eight Lin, Dyan Yen, Wei-Chun HuangFu, Yi-Wen Wu, Jui-Yi Hsu, Shih-Chung Yen, Tzu-Ying Sung, Jui-Hua Hsieh, Shiow-Lin Pan, Chia-Ron Yang and 2 more

Abstract read
In one paragraph

Article in Protein science : a publication of the Protein Society, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Tony Eight LinGraduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.ORCID 0000-0002-6267-0224
Dyan YenGraduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.
Wei-Chun HuangFuGraduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.ORCID 0000-0002-6150-9121
Yi-Wen WuGraduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.ORCID 0000-0002-6625-0630
Jui-Yi HsuGraduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.ORCID 0009-0003-8113-4173
Shih-Chung YenWarshel Institute for Computational Biology, The Chinese University of Hong Kong (Shenzhen), Shenzhen, Guangdong, People's Republic of China.ORCID 0000-0001-8596-0083
Tzu-Ying SungBiomedical Translation Research Center, Academia Sinica, Taipei, Taiwan.
Jui-Hua HsiehDivision of Translational Toxicology, National Institute of Environmental Health Sciences, National Institutes of Health, Durham, North Carolina, USA.ORCID 0000-0003-1620-1571
Shiow-Lin PanGraduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.ORCID 0000-0001-7449-3539
Chia-Ron YangSchool of Pharmacy, College of Medicine, National Taiwan University, Taipei, Taiwan.ORCID 0000-0001-5990-1346
Wei-Jan HuangGraduate Institute of Pharmacognosy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan.ORCID 0000-0001-9548-5829
Kai-Cheng HsuGraduate Institute of Cancer Biology and Drug Discovery, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan.ORCID 0000-0002-9022-6673

Funding

Ministry of Science and Technology, Taiwan MOST 111-2320-B-038-042-MY3Ministry of Science and Technology, Taiwan MOST 112-2320-B-038-051TMU Research Center of Cancer Translational Medicine
6 · The paper itself

Abstract

The identification of an effective inhibitor is an important starting step in drug development. Unfortunately, many issues such as the characterization of protein binding sites, the screening library, materials for assays, etc., make drug screening a difficult proposition. As the size of screening libraries increases, more resources will be inefficiently consumed. Thus, new strategies are needed to preprocess and focus a screening library towards a targeted protein. Herein, we report an ensemble machine learning (ML) model to generate a CDK8-focused screening library. The ensemble model consists of six different algorithms optimized for CDK8 inhibitor classification. The models were trained using a CDK8-specific fragment library along with molecules containing CDK8 activity. The optimized ensemble model processed a commercial library containing 1.6 million molecules. This resulted in a CDK8-focused screening library containing 1,672 molecules, a reduction of more than 99.90%. The CDK8-focused library was then subjected to molecular docking, and 25 candidate compounds were selected. Enzymatic assays confirmed six CDK8 inhibitors, with one compound producing an IC

Indexed as

Cyclin-Dependent Kinase 8Drug Evaluation, PreclinicalMachine LearningProtein Kinase InhibitorsHumansMolecular Docking SimulationSmall Molecule LibrariesCDK8 protein, humanCyclin-Dependent Kinase 8Protein Kinase InhibitorsSmall Molecule LibrariesCDK8fragmentmachine learningmolecular dockingstructure‐based virtual screening

Identifiers

PMID38723187
PMCPMC11081523

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.